Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD47 inhibitor

DRUG CLASS:

CD47 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	PT217 Sensitive: B - Late Trials PT217 Sensitive : B	PT217 Sensitive: B - Late Trials PT217 Sensitive : B
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ONO-7913 Sensitive: C2 – Inclusion Criteria ONO-7913 Sensitive : C2	ONO-7913 Sensitive: C2 – Inclusion Criteria ONO-7913 Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + ONO-7913 Sensitive: C2 – Inclusion Criteria venetoclax + ONO-7913 Sensitive : C2	venetoclax + ONO-7913 Sensitive: C2 – Inclusion Criteria venetoclax + ONO-7913 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	D3L-001 Sensitive: C2 – Inclusion Criteria D3L-001 Sensitive : C2	D3L-001 Sensitive: C2 – Inclusion Criteria D3L-001 Sensitive : C2
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	IMM0306 Sensitive: C2 – Inclusion Criteria IMM0306 Sensitive : C2	IMM0306 Sensitive: C2 – Inclusion Criteria IMM0306 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + ALX148 Sensitive: C3 – Early Trials rituximab + ALX148 Sensitive : C3	rituximab + ALX148 Sensitive: C3 – Early Trials rituximab + ALX148 Sensitive : C3
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
MRC1 expression	Small Cell Lung Cancer	MRC1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3